Study type: In vivo/preclinical · Status: Verified against declared source

Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages.

Antioxidants (Basel, Switzerland) · 2023

Study scale: Total RNA from lung tissues and macrophages was isolated using TRIzol reagent (Vazyme Biotech Co., Ltd, Nanjing, China).

Abstract only: Open source record

Product or molecular entity relationships

SS-31: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

C57BL/6 mice were purchased from SLAC Laboratory Animal Corporation (Shanghai, China).

Methods

Macrophages are the most abundant immune cells, which play a central role during IPF development [4].

Scale or participants

Total RNA from lung tissues and macrophages was isolated using TRIzol reagent (Vazyme Biotech Co., Ltd, Nanjing, China).

Key findings

Idiopathic pulmonary fibrosis (IPF) is a progressive fatal lung disease with a limited therapeutic strategy.

Limitations and uncertainty

Idiopathic pulmonary fibrosis (IPF) is a progressive fatal lung disease with a limited therapeutic strategy.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.